Systemic sclerosis interstitial lung disease: unmet needs and potential solutions

Area of Science:

• Immunology
• Rheumatology
• Pulmonology

Background:

• Systemic sclerosis (SSc), or scleroderma, is a rare, complex autoimmune disease with high morbidity and mortality.
• Cardiopulmonary complications, including interstitial lung disease (ILD) and pulmonary arterial hypertension, are major causes of death in SSc.
• Despite advances in understanding SSc pathogenesis and therapeutic targets, a cure remains elusive.

Purpose of the Study:

• To address the unmet needs in the global management of SSc-related interstitial lung disease.
• To improve early diagnosis, risk stratification, treatment, and monitoring of SSc-ILD.
• To define progression and identify predictors of progression and mortality in SSc-ILD.

Main Methods:

• Review of recent research and clinical trial data on SSc-ILD.
• Analysis of unmet needs in SSc-ILD management.
• Exploration of refined patient stratification strategies based on clinical and molecular features.

Main Results:

• Significant unmet needs persist in the comprehensive management of SSc-ILD.
• Improved patient stratification and outcome measures are crucial for advancing therapeutic strategies.
• Identifying predictors of progression and mortality is essential for better patient care.

Conclusions:

• Further research is needed to address the complex challenges in managing SSc-ILD.
• Refined patient stratification and standardized outcome measures will enhance clinical trial efficacy and patient outcomes.
• Targeted management strategies are required to mitigate the impact of lung involvement in SSc.